FDA 483 - GBS Commonwealth Co., Ltd. - February 20, 2020

An FDA inspection of GBS Commonwealth Co., Ltd., a medical device manufacturer in Geumcheon, Seoul, revealed significant deficiencies across its quality system. The firm failed to adequately manage design controls, validate software, evaluate suppliers, control documents, and maintain personnel training records. These issues indicate a systemic lack of adherence to regulatory requirements for medical device manufacturing.